Gregory D. Plowman

Active 1983–2022

71
Papers
19,370
Citations
68
h-index
71
i10-index

Citations

Citations per year for Gregory D. Plowman1877: 1 citations1984: 2 citations1985: 1 citations1986: 1 citations1987: 4 citations1988: 13 citations1989: 10 citations1990: 32 citations1991: 41 citations1992: 67 citations1993: 49 citations1994: 130 citations1995: 156 citations1996: 188 citations1997: 264 citations1998: 315 citations1999: 297 citations2000: 335 citations2001: 263 citations2002: 253 citations2003: 258 citations2004: 210 citations2005: 175 citations2006: 189 citations2007: 177 citations2008: 256 citations2009: 183 citations2010: 206 citations2011: 227 citations2012: 197 citations2013: 180 citations2014: 147 citations2015: 104 citations2016: 103 citations2017: 114 citations2018: 103 citations2019: 269 citations2020: 334 citations2021: 325 citations2022: 245 citations2023: 187 citations2024: 274 citations2025: 111 citations2026: 5 citations1878–1983: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,116 citing papers, 38.3% of this breakdownUnited Kingdom: 611 citing papers, 7.5% of this breakdownChina: 552 citing papers, 6.8% of this breakdownGermany: 495 citing papers, 6.1% of this breakdownJapan: 400 citing papers, 4.9% of this breakdownFrance: 332 citing papers, 4.1% of this breakdownCanada: 321 citing papers, 4% of this breakdownItaly: 245 citing papers, 3% of this breakdownSwitzerland: 181 citing papers, 2.2% of this breakdownAustralia: 164 citing papers, 2% of this breakdownIsrael: 142 citing papers, 1.8% of this breakdownSpain: 139 citing papers, 1.7% of this breakdown
0%38.3%Other 17.6%

Fields

  • Biochemistry, Genetics and Molecular Biology48.3%
  • Medicine36.3%
  • Neuroscience6.7%
  • Immunology and Microbiology5%
  • Agricultural and Biological Sciences1%
  • Chemistry0.8%
  • Other1.9%

Topics

  • HER2/EGFR in Cancer Research3.6%
  • Microtubule and mitosis dynamics2.9%
  • Cell Adhesion Molecules Research2.8%
  • Angiogenesis and VEGF in Cancer2.7%
  • Monoclonal and Polyclonal Antibodies Research2.5%
  • Protein Kinase Regulation and GTPase Signaling2.3%
  • Other83.2%

Coauthors

All papers

Open in search
  1. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

    Authors: , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2018 cited by 369

  2. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew Z. Dieter, Thompson N. Doman, Shaoyou Chu, Hui-Rong Qian, Xiang S. Ye, David A. Barda, Gregory D. Plowman, Christoph Reinhard, Robert M. Campbell, James R. Henry, Sean G. Buchanan - Cancer Discovery 2018 cited by 233

  3. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 105

  4. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2015 cited by 309

  5. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

    Authors: , , , , , , , , , , , , , , , , - Nature 2006 cited by 989

  6. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Immunology Research 2020 cited by 68

  7. Evolution of protein kinase signaling from yeast to man

    Authors: , , , - Trends in Biochemical Sciences 2002 cited by 994

  8. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

    Authors: , , , , , , , , , , , , , , - Cancer Discovery 2016 cited by 172

  9. ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Cancer Therapeutics 2019 cited by 108

  10. Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Cell 2007 cited by 531

  11. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

    Authors: , , , , , , , , , , , , , - The EMBO Journal 1998 cited by 1,213

  12. Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family

    Authors: , , , , - Science 1989 cited by 597

  13. Protein tyrosine kinase PYK2 involved in Ca2+-induced regulation of ion channel and MAP kinase functions

    Authors: , , , , , , , , - Nature 1995 cited by 1,417

  14. Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew A. Singer, Casey Kopczynski, Daniel Curtis, Thomas C. Kaufman, Gregory D. Plowman, Geoffrey M. Duyk, Helen Francis-Lang - Nature Genetics 2004 cited by 774

  15. Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason R. Manro, Jennie Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martínez, Shripad V. Bhagwat, Emiko L. Kreklau, Marı́a José Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell - Molecular Cancer Therapeutics 2019 cited by 52

  16. Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family.

    Authors: , , , , , - 1995 cited by 162

  17. cDNA Cloning and Sequence Analysis of βig-h3, a Novel Gene Induced in a Human Adenocarcinoma Cell Line after Treatment with Transforming Growth Factor-β

    Authors: , , , , , - DNA and Cell Biology 1992 cited by 514

  18. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.

    Authors: , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1990 cited by 369

  19. Blocking Neuropilin-2 Function Inhibits Tumor Cell Metastasis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2008 cited by 338

  20. Differential expression of epidermal growth factor-related proteins in human colorectal tumors.

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1991 cited by 269

  21. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

    Authors: , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1993 cited by 718

  22. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype.

    Authors: , , , , , , - Journal of Clinical Investigation 1997 cited by 227

  23. Identification of a Novel Family of Targets of PYK2 Related to Drosophila Retinal Degeneration B (rdgB) Protein

    Authors: , , , , , - Molecular and Cellular Biology 1999 cited by 147

  24. Identification of a novel contactin‐associated transmembrane receptor with multiple domains implicated in protein–protein interactions

    Authors: , , , , , , , - The EMBO Journal 1997 cited by 406